| Previous close | 67.89 |
| Open | 68.28 |
| Bid | 69.21 x 1400 |
| Ask | 69.49 x 900 |
| Day's range | 66.10 - 70.00 |
| 52-week range | 13.53 - 95.21 |
| Volume | 13,206,193 |
| Avg. volume | 20,104,903 |
| Market cap | 27.57B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.39 |
| Earnings date | 04 Nov 2020 - 09 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 92.31 |
- Motley Fool
If You Invested $5,000 in Moderna in January, This Is How Much You'd Have Now
The biotech stock has been a big winner so far this year. And it could be an even bigger winner very soon.
- Yahoo Finance
Coronavirus vaccine doesn't depend on President Trump's rhetoric, doctor explains
President Trump recently claimed a vaccine will be available within a few weeks, but Dr. Ezekiel Emanuel stressed that Trump’s claims are only wishful thinking.Â
- Motley Fool
Better Coronavirus Stock: AstraZeneca or Moderna?
Moderna has been a much bigger winner than AstraZeneca year to date. Probably the best argument for buying AstraZeneca instead of Moderna is that it's less risky. AstraZeneca, on the other hand, can more readily absorb any setbacks because of its diversified portfolio.
© 2020 Verizon Media. All rights reserved.
